ARDX
Ardelyx, Inc.6.00
-0.20-3.23%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
Q&A details IBSRELA growth tactics
Q&A unpacked IBSRELA's path to $410M-$430M 2026 guidance, spotlighting doubled field reimbursement managers, a new pharmacy network boosting fulfillment by an extra Rx per patient, and 15-20 added sales roles for reach. Management dismissed frontline payer pursuits, reaffirming 2nd/3rd-line positioning despite hurdles, while CIC approval could lift IBS-C confidence via prescriber familiarity. Trial specs clarified: 95% powered for 18-20% CSBM delta across doses. OpEx ramps early on proven ROI plays. Pull-through is the battleground. Tone stayed bullish; investors eye execution on these levers.
Key Stats
Market Cap
1.46BP/E (TTM)
-Basic EPS (TTM)
-0.23Dividend Yield
0%Recent Filings
8-K
Ardelyx 2025 revenues surge 22%
10-K
FY2025 results
Ardelyx's FY2025 10-K reveals ongoing commercialization of IBSRELA and XPHOZAH amid persistent losses since inception, with XPHOZAH revenue materially hit by ESRD PPS inclusion on January 1, 2025, eliminating Medicare Part D coverage and curbing growth. No quarterly financials disclosed, but executive transitions signal Q4 leadership shifts: David Rosenbaum's planned resignation December 31, 2025, with salary continuation, and Elizabeth Grammer's retirement to advisory role. Non-employee directors earn $50,000 annual retainers plus equity up to $450,000 initial grants. Ongoing losses persist. XPHOZAH reimbursement uncertainty threatens momentum.
8-K
Dual C-suite resignations announced
Ardelyx's Chief Legal Officer Elizabeth Grammer resigns effective December 31, 2025, transitioning to General Counsel then Senior Advisor for 24 months with continued base salary, 2025 bonus eligibility, and COBRA coverage. Chief Medical Officer Edward Conner also exits December 31 for personal reasons—no disagreements. Dr. Laura Williams steps in as interim CMO. Leadership shakeup, but continuity holds.
8-K
Q3 revenue beats, IBSRELA soars
Ardelyx posted Q3 product revenue of $105.5M, up 15% year-over-year, fueled by IBSRELA's $78.2M surge (92% YoY growth) while XPHOZAH added $27.4M amid Medicare coverage loss. Cash stands at $242.7M; IBSRELA full-year guide raised to $270-275M. Pipeline advances with RDX10531 IND planned for 2026. Leadership strengthened.
AARD
Aardvark Therapeutics, Inc.
13.92-0.55
ACLX
Arcellx, Inc.
66.33-2.01
ALDX
Aldeyra Therapeutics, Inc.
5.31+1.32
ARQT
Arcutis Biotherapeutics, Inc.
28.53-0.42
ATXS
Astria Therapeutics, Inc.
12.87-0.05
BLRX
BioLineRx Ltd.
3.01-0.17
EXEL
Exelixis, Inc.
41.60+0.22
NRXS
Neuraxis, Inc.
2.70+0.05
SLNO
Soleno Therapeutics, Inc.
49.50-0.45
ZVRA
Zevra Therapeutics, Inc.
8.12-0.05